



1-29-07

TFW

1624 #

AMENDMENT TRANSMITTAL LETTER				Docket No. LeA 36 080 66817(54716)	
Application No. 10/519,134-Conf. #7514		Filing Date October 7, 2005		Examiner V. Balasubramanian	
				Art Unit 1624	
Applicant(s): Martin Hendrix et al.					
Invention: HETEROCYCLICALLY SUBSTITUTED IMIDAZOTRIAZINES					
TO THE COMMISSIONER FOR PATENTS					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	9	- 20 =		x	
Independent Claims	1	- 3 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Extension for response within first month					120.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					120.00
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input type="checkbox"/> No additional fee is required for this amendment.					
<input checked="" type="checkbox"/> Please charge Deposit Account No. <u>04-1105</u> in the amount of \$ <u>120.00</u> . A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ to cover the filing fee is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>04-1105</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
<u>William F. Gray</u> William F. Gray Attorney/Agent Reg. No.: 31,018				Dated: <u>January 26, 2007</u>	
BAYER PHARMACEUTICALS CORPORATION 400 Morgan Lane West Haven, CT 06516-4175 (203) 812-2712				By: <u>Nicholas V. Costello</u> Reg No. 51,615	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV922748687US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.					
Dated: January 26, 2007		Signature: <u>Denise Kacinski</u> (Denise Kacinski)			



Docket No.: LeA 36 080
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Martin Hendrix et al.

Application No.: 10/519,134

Confirmation No.: 7514

Filed: October 7, 2005

Art Unit: 1624

For: HETEROCYCLICALLY SUBSTITUTED
IMIDAZOTRIAZINES

Examiner: V. Balasubramanian

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated September 26, 2006, please amend the above-identified U.S. patent application as follows. A one month extension of time from December 26, 2006, to and including January 26, 2007, is submitted herewith.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.